6533b852fe1ef96bd12ab88f

RESEARCH PRODUCT

Genetic association of autoimmune hepatitis and human leucocyte antigen in German patients

Anja PiendlAnsgar W. LohseAndreas TeufelMa WörnsCatherine CentnerPeter R. GalleArndt WeinmannStephan Kanzler

subject

MaleImmunogeneticsAutoimmune hepatitisHuman leukocyte antigenAutoantigensHLA-B8 AntigenHLA-DR3 AntigenAntigenimmune system diseasesHLA AntigensGermanyHLA-DQ AntigensmedicineHumansHLA-DQ Antigenmedicine.diagnostic_testbusiness.industryGastroenterologyAutoantibodyGeneral Medicinemedicine.diseasePrognosisdigestive system diseasesHepatitis AutoimmuneGene Expression RegulationItalyLiver biopsyImmunologyNorth AmericaElevated transaminasesFemalebusinessRapid Communication

description

To report on our large German collective and updated data of 142 patients with autoimmune hepatitis (AIH) type 1.Key investigations performed were liver biopsy, serum autoantibodies as well as serum markers such as IgG and elevated transaminases. Antinuclear antigen (ANA) and smooth muscle antigen (SMA) autoantibodies characterized type 1 AIH. Type 3 (AIH) was solely characterized by the occurrence of soluble liver antigen/liver-pancreas antigen (SLA/LP) autoantibodies either with or without ANA or SMA autoantibodies.Most prevalent HLAs were A2 (68 patients, 48%), B8 (63 patients, 44%), C7 (90 patients, 63%), DR3 (49 patients, 38%), DR4 (49 patients, 38%) and DQ2 (42 patients, 30%). Compared to the Italian and North American patients, we found fewer patients with a DQ2 subtype. Furthermore, the B8-DR3-DQ2 human leucocyte antigen (HLA) was also less prominent compared to the North American patients. However, prevalences of B8, DR3, DR4, DR7, DR11 and DR13 were comparable to the Italian and North American patients. Furthermore, we report on an additional subgroup of patients with SLA/LP positive AIH. Generally, in this subgroup of patients the same HLA subtypes were favoured as the AIH type 1.Although HLA subtypes were comparable between these three collectives, the German patients were distinct from the Italian and North American patients with respect to DQ2 and from the North American patients with respect to B8-DR3-DQ2 HLA. A clinical correlation, e.g. difference in severity or treatability of AIH type 1, has yet to be determined.

10.3748/wjg.v12.i34.5513https://europepmc.org/articles/PMC4088235/